Mechanistic understanding of LAI suspension intramuscular depot formation: A physicochemical perspective.

Nilesh Malavia¹, Quanying Bao¹, Daniela Amaral Silva², Khondoker Alam³, Yan Wang³, Viera Lukacova², Diane J Burgess⁴

¹University of Connecticut, Department of Pharmaceutical Sciences, Storrs, CT 06269, USA.

²Simulations Plus, Lancaster, CA, USA.

³Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA.

⁴University of Connecticut, Department of Pharmaceutical Sciences, Storrs, CT 06269, USA. Electronic address: d.burgess@uconn.edu.

PubMed DOI

Abstract

Long-acting injectable (LAI) suspensions have emerged as a promising class of drug delivery systems offering sustained drug release, improved patient adherence, and reduced dosing frequency. However, their in vivo performance remains poorly understood due to the complex interplay of physicochemical and physiological factors governing depot formation at the intramuscular (IM) injection site. The pr…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.